POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Mechanism of action (MOA).
In vitro, POMALYST has been demonstrated to:
- Inhibit the proliferation and induce apoptosis of hematopoietic tumor cells
- Inhibit the proliferation of lenalidomide-resistant multiple myeloma cell lines
- Have immunomodulatory activity. Pomalidomide enhanced T cell- and natural killer cell-mediated immunity
Based on preclinical data:

Based on preclinical in vivo and in vitro studies, the mechanism of action statements are not meant to imply clinical outcomes.
See how POMALYST + dex stimulates immune function and kills multiple myeloma cells.1
IL, interleukin; NK, natural killer; NKT, natural killer T; PI, proteasome inhibitor; TNF, tumor necrosis factor.
*Please see full Prescribing Information, including Boxed WARNINGS, for REVLIMID.
References: 1. POMALYST [package insert]. Summit, NJ: Celgene Corp. 2. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDs) in multiple myeloma. Leukemia. 2010;24(1):22-32.